Predictive nomogram models for atrial fibrillation in COPD patients: A comprehensive analysis of risk factors and prognosis

Huang,Tao; Huang,Xingjie; Cui,Xueying; Dong,Qinghua

doi:10.3892/etm.2024.12459

Predictive nomogram models for atrial fibrillation in COPD patients: A comprehensive analysis of risk factors and prognosis

Authors:
- Tao Huang
- Xingjie Huang
- Xueying Cui
- Qinghua Dong
View Affiliations

Affiliations: Department of Critical Care Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region 541100, P.R. China, Department of Cardiovascular Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region 541100, P.R. China, Department of Reproductive Medical Center, The Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region 541004, P.R. China, Department of Critical Care Medicine, Guilin Municipal Hospital of Traditional Chinese Medicine, Guilin, Guangxi Zhuang Autonomous Region 541000, P.R. China
Published online on: February 28, 2024 https://doi.org/10.3892/etm.2024.12459
Article Number: 171
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to identify the independent risk factors and prognostic indicators for atrial fibrillation (AF) in patients with chronic obstructive pulmonary disease (COPD) and to develop predictive nomogram models. This retrospective study included a total of 286 patients with COPD who were admitted to the Second Affiliated Hospital of Guilin Medical College between January 2020 and May 2022. The average age of the patients was 77.11±8.67 years. Based on the presence or absence of AF, the patients were divided into two groups: The AF group (n=87) and the non‑AF group (n=199). Logistic regression analysis was conducted to identify variables with significant differences between the two groups. Nomogram models were constructed to predict the occurrence of AF in COPD patients and to assess prognosis. Survival analysis was performed using the Kaplan‑Meier method. The follow‑up period for the present study extended until April 31, 2023. Survival time was defined as the duration from the date of the interview to the date the participant succumbed or the end of the follow‑up period. In the present study, age, uric acid (UA) and left atrial diameter (LAD) were found to be independent risk factors for the development of AF in patients diagnosed with COPD. The stepwise logistic regression analysis revealed that age had an odds ratio (OR) of 1.072 [95% confidence interval (CI): 1.019‑1.128; P=0.007], UA had an OR of 1.004 (95% CI: 1.001‑1.008; P=0.010) and LAD had an OR of 1.195 (95% CI: 1.098‑1.301; P<0.001). Univariate and multivariate Cox regression analysis revealed that LAD and UA were independent prognostic factors for long‑term mortality in COPD patients with AF. LAD had a hazard ratio (HR) of 1.104 (95% CI: 1.046‑1.165; P<0.001) and UA had an HR of 1.004 (95% CI: 1.000‑1.008; P=0.042). Based on these findings, predictive nomogram models were developed for AF in COPD patients, which demonstrated good discrimination ability with an area under the curve of 0.886. The prognostic nomogram for COPD patients with AF also showed good predictive accuracy with a concordance index of 0.886 (95% CI: 0.842‑0.930). These models can provide valuable information for risk assessment and prognosis evaluation in clinical practice. Age, UA and LAD are independent risk factors for AF in COPD patients. The developed nomogram models provide a reliable tool for predicting AF in COPD patients and for prognosis assessment.

View Figures

View References

1	Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, Agusti AA and Vogelmeier CF: Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 203:24–36. 2021.PubMed/NCBI View Article : Google Scholar
2	Labaki WW and Rosenberg SR: Chronic obstructive pulmonary disease. Ann Intern Med. 173:ITC17–ITC32. 2020.PubMed/NCBI View Article : Google Scholar
3	Kim V and Criner GJ: Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 187:228–237. 2013.PubMed/NCBI View Article : Google Scholar
4	Ruvuna L and Sood A: Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med. 41:315–327. 2020.PubMed/NCBI View Article : Google Scholar
5	Iheanacho I, Zhang S, King D, Rizzo M and Ismaila AS: Economic burden of chronic obstructive pulmonary disease (COPD): A systematic literature review. Int J Chron Obstruct Pulmon Dis. 15:439–460. 2020.PubMed/NCBI View Article : Google Scholar
6	Negewo NA, Gibson PG and McDonald VM: COPD and its comorbidities: Impact, measurement and mechanisms. Respirology. 20:1160–1171. 2015.PubMed/NCBI View Article : Google Scholar
7	Decramer M, Janssens W and Miravitlles M: Chronic obstructive pulmonary disease. Lancet. 379:1341–1351. 2012.PubMed/NCBI View Article : Google Scholar
8	Lauder L, Mahfoud F, Azizi M, Bhatt DL, Ewen S, Kario K, Parati G, Rossignol P, Schlaich MP, Teo KK, et al: Hypertension management in patients with cardiovascular comorbidities. Eur Heart J. 44:2066–2077. 2023.PubMed/NCBI View Article : Google Scholar
9	Li Z, Zhao H and Wang J: Metabolism and chronic inflammation: The links between chronic heart failure and comorbidities. Front Cardiovasc Med. 8(650278)2021.PubMed/NCBI View Article : Google Scholar
10	Keshishian A, Xie L, Dembek C and Yuce H: Reduction in hospital readmission rates among medicare beneficiaries with chronic obstructive pulmonary disease: A Real-world Outcomes Study of Nebulized Bronchodilators. Clin Ther. 41:2283–2296. 2019.PubMed/NCBI View Article : Google Scholar
11	Zhou T, Liu P, Dhruva SS, Shah ND, Ramachandran R, Berg KM and Ross JS: Assessment of hypothetical out-of-pocket costs of guideline-recommended medications for the treatment of older adults with multiple chronic conditions, 2009 and 2019. JAMA Intern Med. 182:185–195. 2022.PubMed/NCBI View Article : Google Scholar
12	Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, et al: Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation. 129:837–847. 2014.PubMed/NCBI View Article : Google Scholar
13	Romiti GF, Corica B, Pipitone E, Vitolo M, Raparelli V, Basili S, Boriani G, Harari S, Lip GYH and Proietti M: AF-COMET International Collaborative Group. Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: A systematic review and meta-analysis of 4,200,000 patients. Eur Heart J. 42:3541–3554. 2021.PubMed/NCBI View Article : Google Scholar
14	Goudis CA, Konstantinidis AK, Ntalas IV and Korantzopoulos P: Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease. Int J Cardiol. 199:264–273. 2015.PubMed/NCBI View Article : Google Scholar
15	Naser N, Dilic M, Durak A, Kulic M, Pepic E, Smajic E and Kusljugic Z: The impact of risk factors and comorbidities on the incidence of atrial fibrillation. Mater Sociomed. 29:231–236. 2017.PubMed/NCBI View Article : Google Scholar
16	Huang Q, Xiong H, Shuai T, Zhang M, Zhang C, Wang Y, Zhu L, Lu J and Liu J: Risk factors for new-onset atrial fibrillation in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. PeerJ. 8(e10376)2020.PubMed/NCBI View Article : Google Scholar
17	Wood-Baker R, Cochrane B and Naughton MT: Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: The impact of bronchodilator treatment. Intern Med J. 40:94–101. 2010.PubMed/NCBI View Article : Google Scholar
18	Tousoulis D: Biomarkers in atrial fibrillation; From pathophysiology to diagnosis and treatment. Curr Med Chem. 26:762–764. 2019.PubMed/NCBI View Article : Google Scholar
19	Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, et al: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 61(2200879)2023.PubMed/NCBI View Article : Google Scholar
20	Ranstam J and Cook JA: Kaplan-Meier curve. Br J Surg. 104(442)2017.PubMed/NCBI View Article : Google Scholar
21	Abraham CR and Li A: Aging-suppressor Klotho: Prospects in diagnostics and therapeutics. Ageing Res Rev. 82(101766)2022.PubMed/NCBI View Article : Google Scholar
22	Guo Y, Tian Y, Wang H, Si Q, Wang Y and Lip GYH: Prevalence, incidence, and lifetime risk of atrial fibrillation in China: New insights into the global burden of atrial fibrillation. Chest. 147:109–119. 2015.PubMed/NCBI View Article : Google Scholar
23	Koshiyama M, Tamaki K and Ohsawa M: Age-specific incidence rates of atrial fibrillation and risk factors for the future development of atrial fibrillation in the Japanese general population. J Cardiol. 77:88–92. 2021.PubMed/NCBI View Article : Google Scholar
24	McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, Wright AC, Gefter WB, Litzky L, Coxson HO, et al: Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 365:1567–1575. 2011.PubMed/NCBI View Article : Google Scholar
25	Guo J, Chen Y, Zhang W, Tong S and Dong J: Moderate and severe exacerbations have a significant impact on health-related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis. Int J Surg. 78:28–35. 2020.PubMed/NCBI View Article : Google Scholar
26	Soeki T, Matsuura T, Tobiume T, Bando S, Matsumoto K, Nagano H, Uematsu E, Kusunose K, Ise T, Yamaguchi K, et al: Clinical, electrocardiographic, and echocardiographic parameter combination predicts the onset of atrial fibrillation. Circ J. 82:2253–2258. 2018.PubMed/NCBI View Article : Google Scholar
27	Debonnaire P, Joyce E, Hiemstra Y, Mertens BJ, Atsma DE, Schalij MJ, Bax JJ, Delgado V and Marsan NA: Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation. Circ Arrhythm Electrophysiol. 10(e004052)2017.PubMed/NCBI View Article : Google Scholar
28	Vaziri SM, Larson MG, Benjamin EJ and Levy D: Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation. 89:724–730. 1994.PubMed/NCBI View Article : Google Scholar
29	Alfadhel M, Nestelberger T, Samuel R, McAlister C and Saw J: Left atrial appendage closure-Current status and future directions. Prog Cardiovasc Dis. 69:101–109. 2021.PubMed/NCBI View Article : Google Scholar
30	Mo BF, Lian XM and Li YG: Current evidence on the safety and efficacy of combined atrial fibrillation ablation and left atrial appendage closure. Curr Opin Cardiol. 37:74–79. 2022.PubMed/NCBI View Article : Google Scholar
31	Zhang H, Tang Z, Han Z, Zeng L and Wang C: Role of real time-three dimensional transesophageal echocardiography in left atrial appendage closure with LACBES(®) devices. Exp Ther Med. 17:1456–1462. 2019.PubMed/NCBI View Article : Google Scholar
32	Zhang Q, Wang JF, Dong QQ, Yan Q, Luo XH, Wu XY, Liu J and Sun YP: Evaluation of left atrial volume and function using single-beat real-time three-dimensional echocardiography in atrial fibrillation patients. BMC Med Imaging. 17(44)2017.PubMed/NCBI View Article : Google Scholar
33	Sagris M, Vardas EP, Theofilis P, Antonopoulos AS, Oikonomou E and Tousoulis D: Atrial fibrillation: Pathogenesis, predisposing factors, and genetics. Int J Mol Sci. 23(6)2021.PubMed/NCBI View Article : Google Scholar
34	Hu YF, Chen YJ, Lin YJ and Chen SA: Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 12:230–243. 2015.PubMed/NCBI View Article : Google Scholar
35	Khalid K, Padda J, Komissarov A, Colaco LB, Padda S, Khan AS, Campos VM and Jean-Charles G: The coexistence of chronic obstructive pulmonary disease and heart failure. Cureus. 13(e17387)2021.PubMed/NCBI View Article : Google Scholar
36	Canepa M, Franssen FME, Olschewski H, Lainscak M, Böhm M, Tavazzi L and Rosenkranz S: Diagnostic and therapeutic gaps in patients with heart failure and chronic obstructive pulmonary disease. JACC Heart Fail. 7:823–833. 2019.PubMed/NCBI View Article : Google Scholar
37	Grymonprez M, Vakaet V, Kavousi M, Stricker BH, Ikram MA, Heeringa J, Franco OH, Brusselle GG and Lahousse L: Chronic obstructive pulmonary disease and the development of atrial fibrillation. Int J Cardiol. 276:118–124. 2019.PubMed/NCBI View Article : Google Scholar
38	Jesel L, Abbas M, Toti F, Cohen A, Arentz T and Morel O: Microparticles in atrial fibrillation: A link between cell activation or apoptosis, tissue remodelling and thrombogenicity. Int J Cardiol. 168:660–669. 2013.PubMed/NCBI View Article : Google Scholar
39	Liu N, Xu H, Sun Q, Yu X, Chen W, Wei H, Jiang J, Xu Y and Lu W: The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors. Oxid Med Cell Longev. 2021(1470380)2021.PubMed/NCBI View Article : Google Scholar
40	Durmus Kocak N, Sasak G, Aka Akturk U, Akgun M, Boga S, Sengul A, Gungor S and Arinc S: Serum uric acid levels and uric acid/creatinine ratios in stable chronic obstructive pulmonary disease (COPD) patients: Are these parameters efficient predictors of patients at risk for exacerbation and/or severity of disease? Med Sci Monit. 22:4169–4176. 2016.PubMed/NCBI View Article : Google Scholar
41	Park JH, Jo YI and Lee JH: Renal effects of uric acid: Hyperuricemia and hypouricemia. Korean J Intern Med. 35:1291–1304. 2020.PubMed/NCBI View Article : Google Scholar
42	Hu L, Hu G, Xu BP, Zhu L, Zhou W, Wang T, Bao H and Cheng X: U-Shaped association of serum uric acid with all-cause and cause-specific mortality in US adults: A cohort study. J Clin Endocrinol Metab. 105(dgz068)2020.PubMed/NCBI View Article : Google Scholar
43	Uk Kang T, Park KY, Kim HJ, Ahn HS, Yim SY and Jun JB: Association of hyperuricemia and pulmonary hypertension: A systematic review and meta-analysis. Mod Rheumatol. 29:1031–1041. 2019.PubMed/NCBI View Article : Google Scholar
44	Wu ZD, Yang XK, He YS, Ni J, Wang J, Yin KJ, Huang JX, Chen Y, Feng YT, Wang P and Pan HF: Environmental factors and risk of gout. Environ Res. 212(Pt C)(113377)2022.PubMed/NCBI View Article : Google Scholar
45	Li S, Cheng J, Cui L, Gurol ME, Bhatt DL, Fonarow GC, Benjamin EJ, Xing A, Xia Y, Wu S and Gao X: Cohort study of repeated measurements of serum urate and risk of incident atrial fibrillation. J Am Heart Assoc. 8(e012020)2019.PubMed/NCBI View Article : Google Scholar
46	Crawley WT, Jungels CG, Stenmark KR and Fini MA: U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia. Redox Biol. 51(102271)2022.PubMed/NCBI View Article : Google Scholar
47	Yang Y, Tian J, Zeng C, Wei J, Li LJ, Xie X, Yang T, Li H and Lei GH: Relationship between hyperuricemia and risk of coronary heart disease in a middle-aged and elderly Chinese population. J Int Med Res. 45:254–260. 2017.PubMed/NCBI View Article : Google Scholar
48	Perez-Ruiz F and Becker MA: Inflammation: A possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 31 (Suppl 2):S9–S14. 2015.PubMed/NCBI View Article : Google Scholar
49	Li N, Zhang S, Li W, Wang L, Liu H, Li W, Zhang T, Liu G, Du Y and Leng J: Prevalence of hyperuricemia and its related risk factors among preschool children from China. Sci Rep. 7(9448)2017.PubMed/NCBI View Article : Google Scholar
50	Chao TF, Hung CL, Chen SJ, Wang KL, Chen TJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC and Chen SA: The association between hyperuricemia, left atrial size and new-onset atrial fibrillation. Int J Cardiol. 168:4027–4032. 2013.PubMed/NCBI View Article : Google Scholar